Cosmos Health Inc - SIC # 5122 - DRUGS, DRUG PROPRIETARIES, AND DRUGGISTS SUNDRIES

Ticker Exchange SIC # Website Latest Ticker
COSM Nasdaq 5122 https://www.cosmosholdingsinc.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cosmos Health Inc

Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform - Mar 21st, 2024 1:45 pm
Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market - Mar 19th, 2024 2:10 pm
Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders - Mar 18th, 2024 1:25 pm
Cosmos Health Successfully Completes Acquisition of Pharmatrade’s Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million - Feb 29th, 2024 2:25 pm
As Trading Frenzies Grip Penny Stocks, Criticism of Nasdaq Grows - Feb 23rd, 2024 5:00 am
Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price - Feb 21st, 2024 4:50 pm
Taglich Brothers Initiates Coverage of Cosmos Health Inc. - Feb 21st, 2024 2:30 pm
Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company - Feb 20th, 2024 2:25 pm
Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market - Jan 23rd, 2024 6:05 pm
Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio - Jan 18th, 2024 2:25 pm
Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023 - Dec 27th, 2023 2:27 pm
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X - Dec 20th, 2023 2:15 pm
Cosmos Health Announces Open Market Stock Purchases by the CEO - Dec 18th, 2023 2:15 pm
Cosmos Health to Participate at Capital Link’s 'Invest in Greece' Forum in New York - Dec 8th, 2023 5:45 pm
Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers - Dec 7th, 2023 2:35 pm
Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product - Dec 1st, 2023 3:25 pm
Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share - Nov 21st, 2023 2:00 pm
Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders - Oct 11th, 2023 1:35 pm
COSMOS HEALTH CEO Issues Letter to Shareholders - Oct 5th, 2023 12:30 pm
Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company - Sep 27th, 2023 2:30 pm